COVID-19 Neurologic Complications
To go to the COVID-19 project topics list, click here.
|
COVID-19 Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
COVID-19 Neurologic Complications On the Web |
|
American Roentgen Ray Society Images of COVID-19 Neurologic Complications |
|
Risk calculators and risk factors for COVID-19 Neurologic Complications |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D., Rinky Agnes Botleroo, M.B.B.S.
Overview
Pathophysiology of the Complications in the Nervous System
Mechanism of targetting the Nervous System
Complications in the Central Nervous System
Headache
- Pathophysiology
- Natural history
- Sign and symptoms
- Diagnosis
- Treatment
Cerebrovascular Accident/Stroke
- Pathophysiology
- Natural history
- Sign and symptoms
- Diagnosis
- Treatment
Acute Encephalitis
- Pathophysiology
- Natural history
- Sign and symptoms
- Diagnosis
- Treatment
Viral Meningitis
- Pathophysiology
- Natural history
- Sign and symptoms
- Diagnosis
- Treatment
Epileptic Seizures
- Pathophysiology
- Natural history
- Sign and symptoms
- Diagnosis
- Treatment
Encephalopathy
- Pathophysiology
- Natural history
- Sign and symptoms
- Diagnosis
- Treatment
Complications in the Peripheral Nervous system
Guillain-Barre syndrome
- Pathophysiology
- Natural history
- Sign and symptoms
- Diagnosis
- Treatment
Anosmia
- Pathophysiology
- Natural history
- Sign and symptoms
- Diagnosis
- Treatment
Acute Myelitis
- Pathophysiology
- Natural history
- Sign and symptoms
- Diagnosis
- Treatment
Miller Fischer Sydrome
- Pathophysiology
- Natural history
- Sign and symptoms
- Diagnosis
- Treatment
Polyneuritis Cranialis
- Pathophysiology
- Natural history
- Sign and symptoms
- Diagnosis
- Treatment
Complications due to medication interaction
1. Statin induced myotoxicity
- Myalgia, myopathies, rhabdomyolysis
2. 2nd and 3rd degree atrioventricular block
- Lopinavir/ Ritonavir (Kaltera) (400 mg/100 mg)
3. Prolong QTc interval
- Chloroquine/Hydroxychloroquine
4. Myelotoxicity
- Ribavirin
5. Prolonged PR interval
- Atazanavir
6. Myelosuppression
7.
References
- ↑ St-Jean JR, Jacomy H, Desforges M, Vabret A, Freymuth F, Talbot PJ (August 2004). "Human respiratory coronavirus OC43: genetic stability and neuroinvasion". J. Virol. 78 (16): 8824–34. doi:10.1128/JVI.78.16.8824-8834.2004. PMC 479063. PMID 15280490.
- ↑ Huang, Chaolin; Wang, Yeming; Li, Xingwang; Ren, Lili; Zhao, Jianping; Hu, Yi; Zhang, Li; Fan, Guohui; Xu, Jiuyang; Gu, Xiaoying; Cheng, Zhenshun; Yu, Ting; Xia, Jiaan; Wei, Yuan; Wu, Wenjuan; Xie, Xuelei; Yin, Wen; Li, Hui; Liu, Min; Xiao, Yan; Gao, Hong; Guo, Li; Xie, Jungang; Wang, Guangfa; Jiang, Rongmeng; Gao, Zhancheng; Jin, Qi; Wang, Jianwei; Cao, Bin (2020). "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China". The Lancet. 395 (10223): 497–506. doi:10.1016/S0140-6736(20)30183-5. ISSN 0140-6736.
- ↑ Rossi, Andrea (2008). "Imaging of Acute Disseminated Encephalomyelitis". Neuroimaging Clinics of North America. 18 (1): 149–161. doi:10.1016/j.nic.2007.12.007. ISSN 1052-5149.